DAVENPORT & Co LLC Sells 51,708 Shares of HealthEquity, Inc. (NASDAQ:HQY)

DAVENPORT & Co LLC decreased its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 13.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 344,181 shares of the company's stock after selling 51,708 shares during the quarter. DAVENPORT & Co LLC owned about 0.40% of HealthEquity worth $30,415,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Summit Trail Advisors LLC grew its holdings in HealthEquity by 16.2% during the first quarter. Summit Trail Advisors LLC now owns 3,636 shares of the company's stock valued at $321,000 after purchasing an additional 508 shares during the period. Vontobel Holding Ltd. grew its holdings in HealthEquity by 10.9% during the first quarter. Vontobel Holding Ltd. now owns 14,821 shares of the company's stock valued at $1,310,000 after purchasing an additional 1,456 shares during the period. ABLE Financial Group LLC grew its holdings in HealthEquity by 4.4% during the first quarter. ABLE Financial Group LLC now owns 22,671 shares of the company's stock valued at $2,003,000 after purchasing an additional 946 shares during the period. New York State Teachers Retirement System grew its holdings in HealthEquity by 2.6% during the first quarter. New York State Teachers Retirement System now owns 84,675 shares of the company's stock valued at $7,483,000 after purchasing an additional 2,124 shares during the period. Finally, Lisanti Capital Growth LLC grew its holdings in HealthEquity by 467.5% during the first quarter. Lisanti Capital Growth LLC now owns 47,100 shares of the company's stock valued at $4,162,000 after purchasing an additional 38,800 shares during the period. Institutional investors and hedge funds own 99.55% of the company's stock.

HealthEquity Stock Down 1.7%

Shares of HQY stock traded down $1.73 during trading on Friday, reaching $99.55. The company's stock had a trading volume of 627,812 shares, compared to its average volume of 862,960. The business has a fifty day moving average price of $99.74 and a 200-day moving average price of $98.29. The company has a quick ratio of 4.06, a current ratio of 4.06 and a debt-to-equity ratio of 0.50. The company has a market cap of $8.61 billion, a price-to-earnings ratio of 72.66, a price-to-earnings-growth ratio of 1.57 and a beta of 0.49. HealthEquity, Inc. has a one year low of $65.01 and a one year high of $116.65.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings data on Tuesday, June 3rd. The company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. The business had revenue of $330.80 million for the quarter, compared to analyst estimates of $322.25 million. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. During the same quarter in the previous year, the firm posted $0.80 earnings per share. Analysts anticipate that HealthEquity, Inc. will post 2.32 earnings per share for the current year.

Insiders Place Their Bets

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of the company's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total transaction of $446,487.50. Following the sale, the director directly owned 84,969 shares of the company's stock, valued at approximately $6,597,842.85. This represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jon Kessler sold 97,767 shares of the company's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $112.05, for a total transaction of $10,954,792.35. Following the sale, the director directly owned 75,000 shares in the company, valued at $8,403,750. This trade represents a 56.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 295,700 shares of company stock valued at $32,968,990. 1.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on HQY shares. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, June 5th. Barrington Research upped their price target on shares of HealthEquity from $112.00 to $125.00 and gave the company an "outperform" rating in a report on Thursday, June 5th. Royal Bank Of Canada upped their price target on shares of HealthEquity from $112.00 to $117.00 and gave the company an "outperform" rating in a report on Wednesday, June 4th. Wall Street Zen upgraded shares of HealthEquity from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Finally, Raymond James Financial upgraded shares of HealthEquity from an "outperform" rating to a "strong-buy" rating and reduced their price target for the company from $120.00 to $115.00 in a report on Tuesday, March 25th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, HealthEquity presently has a consensus rating of "Buy" and an average target price of $118.09.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.